
KLAUS K. WILGENBUS MD

±49 (0) 15251607777

klaus.wilgenbus@gmail.com

Hess Str. 6
65189 Wiesbaden

Germany

Profile

Klaus K. Wilgenbus (KKW) is an independent healthcare analyst and consultant with a proven track record as a senior leader in drug discovery, deal making (personally involved in more than 200 strategic transactions incl. R&D collaborations, co-promotion and co-marketing alliances, JV's and merger and acquisitions), innovation management, corporate strategy and restructuring of large R&D as well as commercial organizations. KKW recently retired from Boehringer Ingelheim (BI) as Corp Sen. VP Business Development, Licensing and Strategy after 18 successful years in different management positions. KKW was a member of various top management committees at BI responsible to steer BI's global commercial as well as R&D activities. He also served on various boards of BI-affiliated companies incl. Actimis Inc. (San Diego) and Boehringer Ingelheim Germany. He also represented BI at the Board of (US) BIO and currently serves as an independent board member at Karolinska Development AB (publ.).

Professional Experience

Corp. Sen. VP Business Development, Licensing & Strategy Boehringer Ingelheim GmbH; 01/2010 – 8/2014

- Responsible for all partnering and business development activities from early discovery to commercial phase for BI's human pharma business.
 - Lead annual strategy review cycle, portfolio management and oversaw all project initiatives for human pharma business.
 - Member of senior management committee steering BI's global ethical hum pharma business.
 - Project leader of various global large-scale restructuring projects (e.g. adapting European commercial organization to new market access environment and closing down R&D site in Laval Canada).
 - Conceived and established an internal innovation incubator focusing on potentially disruptive innovation in adjacent areas of healthcare like healthcare IT, mobile health, social media, etc.
 - Line responsibility for a global team of about 45 managers and experts located in the US, Germany, China and Japan.
 - Reporting line: Executive Board Member Human Pharma
-

Corp. Sen. VP Licensing

Boehringer Ingelheim GmbH; 01/2004 - 12/2009

- Responsible for all partnering and business development activities from early discovery to commercial phase for BI's human pharma business.
- Supervised and steered BI's global Competitive Technology Analysis activities.
- Conceived and implemented BI's Corporate Venture Fund. Served as member of investment committee until 2012.
- Line responsibility for a global team of about 35 managers and experts located in the US, Germany and Japan.
- Reporting line: Executive Board Member R&D and Medicine

Corp. VP R&D Licensing

Boehringer Ingelheim GmbH; 04/2001 - 12/2003

- Implemented newly established global function within BI's R&D organization managing all partnering activities from early discovery to phase 1.
- Member of various management committees steering BI's global R&D activities
- Line responsibility for a global team of about 20 managers and experts located in the US, Germany and Japan.
- Reporting line: Corp. Sen. VP R&D

Director Exploratory Research

Boehringer Ingelheim Austria (Vienna); 07/1998 - 03/2001

- Responsible for target discovery, assay development and lead identification in Oncology
 - Member of various management committee steering BI's entire R&D efforts in Oncology
 - Project leader: Global R&D IT system for target discovery
-

Team Leader Genomics & Bioinformatics

Boehringer Ingelheim Austria (Vienna); 09/1996 - 06/1998

- Established first Genomics and Bioinformatics group at BI
- Lead various global teams to establish similar Genomics and Bioinformatics groups at other R&D sites (US and Germany).

Academic Career & Education

- Postgraduate training as human pathologist and molecular geneticist at various academic institutions incl. German Cancer Research Center, Stanford University and RWTH Aachen.
 - Thesis (1990): Comparative analysis of gap junction in normal and malignant human tissues (RWTH Aachen, magna cum laude)
 - Graduation as MD (11/89): RWTH Aachen, Germany
 - Various stipends and fellowships (Postdoctoral fellowship: German Research Foundation: Stanford University, CA; Student fellowship German Academic Exchange Service: Brown University, RI)
 - Over 20 peer-reviewed publications in the field of complex genome analysis, molecular genetics, human genetics and molecular pathology.
-